论文部分内容阅读
目的:研究血管内皮生长因子165(VEGF_(165))对血管内皮细胞药物敏感性的影响。方法:人真皮微血管内皮细胞(HDMEC)与抗癌药物和VEGF_(165)混合培养,MTT法分析药敏变化,琼脂糖电泳检测细胞凋亡,RT-PCR、免疫印迹法分析HDMEC产生多药耐药表型的机制。结果:VEGF_(165)体外诱导HDMEC对多种抗癌药物耐药,如表柔比星、顺铂、足叶乙甙、丝裂霉素C、长春新碱、CPT-11、泰素等,其机制与VEGF_(165)诱导HDMEC上调表达多药耐药相关蛋白和肺耐药相关蛋以及下调表达Bax蛋白有关。结论:VEGF_(165)诱导血管内皮细胞的多药耐药表型,提示化疗时抗癌药物的抗血管生成活性可能取决于肿瘤微环境。
Objective: To study the effect of vascular endothelial growth factor 165 (VEGF_(165)) on the drug sensitivity of vascular endothelial cells. METHODS: Human dermal microvascular endothelial cells (HDMEC) were mixed with anticancer drugs and VEGF_(165). MTT assay was used to analyze drug sensitivity changes. Apoptosis was detected by agarose electrophoresis. RT-PCR and immunoblotting were used to analyze HDMEC multidrug resistance. Phenotypic mechanism. RESULTS: VEGF_(165) induced HDMEC resistance to several anticancer drugs in vitro, such as epirubicin, cisplatin, etoposide, mitomycin C, vincristine, CPT-11, taxol, etc. Its mechanism is related to the up-regulation of VEGF_(165)-induced HDMEC expression of multidrug resistance-associated proteins, lung resistance-associated eggs, and down-regulation of Bax protein expression. CONCLUSION: The VEGF_(165)-induced multidrug resistance phenotype of vascular endothelial cells suggests that the anti-angiogenic activity of anticancer drugs during chemotherapy may depend on the tumor microenvironment.